MX2021007001A - Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. - Google Patents
Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.Info
- Publication number
- MX2021007001A MX2021007001A MX2021007001A MX2021007001A MX2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A MX 2021007001 A MX2021007001 A MX 2021007001A
- Authority
- MX
- Mexico
- Prior art keywords
- double
- nucleic acid
- acid inhibitor
- tribucle
- inhibitor molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778759P | 2018-12-12 | 2018-12-12 | |
| PCT/US2019/061241 WO2020123083A1 (en) | 2018-12-12 | 2019-11-13 | Double-stranded nucleic acid inhibitor molecules containing a triloop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007001A true MX2021007001A (es) | 2021-10-13 |
Family
ID=71076672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007001A MX2021007001A (es) | 2018-12-12 | 2019-11-13 | Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220064640A1 (enExample) |
| EP (1) | EP3894560A4 (enExample) |
| JP (2) | JP7535047B2 (enExample) |
| KR (1) | KR20210127917A (enExample) |
| CN (1) | CN113454221A (enExample) |
| AU (1) | AU2019397247A1 (enExample) |
| BR (1) | BR112021011294A2 (enExample) |
| CA (1) | CA3122930A1 (enExample) |
| CL (1) | CL2021001552A1 (enExample) |
| IL (1) | IL283775A (enExample) |
| MX (1) | MX2021007001A (enExample) |
| SG (1) | SG11202106046XA (enExample) |
| WO (1) | WO2020123083A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123083A1 (en) * | 2018-12-12 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules containing a triloop |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| CA3190481A1 (en) * | 2020-08-04 | 2022-02-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting plp1 expression |
| AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
| WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
| US20230374522A1 (en) * | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
| WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
| WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891216B1 (en) * | 2005-05-25 | 2012-02-22 | The University Of York | Hybrid interfering rna |
| DK2341943T3 (en) * | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| CN102264898B (zh) * | 2008-10-23 | 2013-10-16 | 国立大学法人东京大学 | 微小rna的功能抑制方法 |
| EP2562257A4 (en) * | 2010-04-19 | 2014-10-01 | Riken | PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS |
| JP6091424B2 (ja) * | 2011-11-16 | 2017-03-08 | 公立大学法人大阪市立大学 | ＲＮＡｉ分子の活性を抑制するための核酸分子 |
| DK3569711T3 (da) * | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| US10821112B2 (en) * | 2016-03-16 | 2020-11-03 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| HUE059718T2 (hu) * | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| IL271680B (en) * | 2017-06-29 | 2022-09-01 | Dicerna Pharmaceuticals Inc | Compositions and methods for inhibiting hmgb1 expression |
| JP2021520355A (ja) * | 2018-04-13 | 2021-08-19 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｔｍ上昇ヌクレオチドで修飾された二本鎖核酸阻害剤分子 |
| WO2020123083A1 (en) * | 2018-12-12 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules containing a triloop |
-
2019
- 2019-11-13 WO PCT/US2019/061241 patent/WO2020123083A1/en not_active Ceased
- 2019-11-13 JP JP2021534224A patent/JP7535047B2/ja active Active
- 2019-11-13 AU AU2019397247A patent/AU2019397247A1/en not_active Abandoned
- 2019-11-13 CN CN201980091916.3A patent/CN113454221A/zh not_active Withdrawn
- 2019-11-13 SG SG11202106046XA patent/SG11202106046XA/en unknown
- 2019-11-13 KR KR1020217021547A patent/KR20210127917A/ko not_active Ceased
- 2019-11-13 CA CA3122930A patent/CA3122930A1/en active Pending
- 2019-11-13 US US17/311,949 patent/US20220064640A1/en not_active Abandoned
- 2019-11-13 MX MX2021007001A patent/MX2021007001A/es unknown
- 2019-11-13 BR BR112021011294-4A patent/BR112021011294A2/pt not_active IP Right Cessation
- 2019-11-13 EP EP19895099.0A patent/EP3894560A4/en active Pending
-
2021
- 2021-06-07 IL IL283775A patent/IL283775A/en unknown
- 2021-06-11 CL CL2021001552A patent/CL2021001552A1/es unknown
-
2024
- 2024-04-24 JP JP2024070175A patent/JP7748500B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122930A1 (en) | 2020-06-18 |
| JP7748500B2 (ja) | 2025-10-02 |
| US20220064640A1 (en) | 2022-03-03 |
| JP2022521877A (ja) | 2022-04-13 |
| EP3894560A1 (en) | 2021-10-20 |
| EP3894560A4 (en) | 2022-10-19 |
| AU2019397247A1 (en) | 2021-06-24 |
| BR112021011294A2 (pt) | 2021-08-31 |
| WO2020123083A1 (en) | 2020-06-18 |
| IL283775A (en) | 2021-07-29 |
| CL2021001552A1 (es) | 2021-11-26 |
| JP2024109582A (ja) | 2024-08-14 |
| JP7535047B2 (ja) | 2024-08-15 |
| SG11202106046XA (en) | 2021-07-29 |
| KR20210127917A (ko) | 2021-10-25 |
| CN113454221A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007001A (es) | Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle. | |
| CO2020001354A2 (es) | Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores). | |
| MX2020012048A (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el angiotensinogeno (agt) y metodos para su uso. | |
| JOP20200115A1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| JOP20200142A1 (ar) | بنيات rnai لتثبيط التعبير عن pnpla3 وطرق استخدامها | |
| MX2020010802A (es) | Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm. | |
| EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
| CL2021001490A1 (es) | Constructos de iarn modificados químicamente y usos de estos | |
| MX2022012561A (es) | Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a). | |
| MX2024009873A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
| EA201792444A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ФАКТОРА XII (ФАКТОРА ХАГЕМАНА) (F12), ПЛАЗМЕННОГО КАЛЛИКРЕИНА B (ФАКТОРА ФЛЕТЧЕРА) 1 (KLKB1) И КИНИНОГЕНА 1 (KNG1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA202191629A1 (ru) | Конструкции для rnai, предназначенные для подавления экспрессии pnpla3 | |
| AR120341A1 (es) | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO | |
| PE20241933A1 (es) | Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt) | |
| CL2021001488A1 (es) | Transposasa de piggybac mutada | |
| MX2016004319A (es) | Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1). | |
| WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
| BR112021006520A2 (pt) | ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar | |
| JOP20190112A1 (ar) | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي | |
| MX2017011298A (es) | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. | |
| MX2025010451A (es) | Composiciones y métodos para la inhibición de la expresión de genes de la subunidad beta e de la inhibina (inhbe) | |
| CL2021002842A1 (es) | Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas | |
| CO2020001106A2 (es) | Agente terapéutico para fibrosis | |
| AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
| MX2022012493A (es) | Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc). |